Sep 2, 2022: CKDu, mechanisms and therapeutic targets

Black and white formal photo of seminar speaker, David Sheikh-Hamad, MD

David Sheikh-Hamad, MD

Professor of Medicine, Molecular & Cellular Biology

Baylor College of Medicine

He / Him / His


Mesoamerican nephropathy is an epidemic of kidney failure affecting farm workers (predominantly male) in Central America; similar disease [aka, chronic kidney disease of unknown etiology (CKDu)] affects agricultural communities world-wide. We surveyed migrant workers with kidney failure at a Harris Health-based dialysis unit and discovered a link between exposure to agrochemicals (especially paraquat) and kidney failure. Weekly injections of sub-toxic doses of paraquat to mice for 15 weeks resulted in kidney failure – similar to Mesoamerican nephropathy. The study also examines kidney transporters for paraquat (OCT2 and MATE1), and finds a similar pattern in kidney biopsies of patients with Mesoamerican nephropathy. Data detailing these findings will appear in a September issue of CJASN.

About the Speaker: Dr. Sheikh-Hamad earned his MD degree from the Hebrew University-Hadassah Medical School, Jerusalem, Israel. After completing rotating internship at the Rambam Hospital in Haifa/Israel, he moved to the US and completed residency in Internal Medicine and Fellowship in Nephrology at the UCLA/San Fernando Valley Program, Los Angeles/California. This was followed by NRSA Fellowship in the Lab of Kidney and Electrolytes Metabolism (LKEM)/NHLBI/NIH under the mentorship of Dr. Maurice Burg. He was then recruited as an Assistant Professor in the Division of Nephrology/Department of Medicine, Baylor College of Medicine, Houston/Texas. He rose through the ranks, and is currently a tenured Professor in the Departments of Medicine, and Molecular & Cellular Biology; he is Director for basic research in the Selzman Institute for Kidney Health/Division of Nephrology, Baylor College of Medicine. He served as Chief of Renal Services at the Ben Taub General Hospital from 2000-2020 and established a unique outpatient dialysis program at Riverside that provides Medicare-equivalent care for unfunded community patients with ESKD. His research focuses on mechanisms of ischemic AKI, and specifically on protective mitochondrial pathways (STC1/AMPK/SIRT3). Most recently, his lab identified megalin as a shuttle for hormones from the cell surface to the mitochondria. Throughout his career, he was funded through the NIH/AHA and VA.

Friday, September 2, 2022, 12:00-1:15 pm Eastern

Field Auditorium Room 1112, Grainger Hall (9 Circuit Dr, Durham, NC)

Masks are REQUIRED regardless of vaccination status. Please stay home if you aren’t feeling well – you may attend via Zoom instead (see below).

This seminar will also be presented live via Zoom.

Register HERE to receive a Zoom link for our entire Fall 2022 seminar series!

You only need to register ONCE to receive the link for our entire fall series

Return to the Fall 2022 Seminar Series main page